Metraipolis › archive › dc_18fc2f763f13
Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells — Europe PMC PMID:41221272
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41221272
- DOI
- 10.3389/fimmu.2025.1711448
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T01:04:57.866Z
- SHA-256 of the archived text
07337d6d96d97abf2305e3b954ca3ba0827c976f12d61f0ae35536425779f049- Stable URL of this page
https://metraipolis.com/documento/dc_18fc2f763f13
How to cite
Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells — Europe PMC PMID:41221272 — Europe PMC (en), https://europepmc.org/article/MED/41221272 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_18fc2f763f13 (Metraipolis archive dc_18fc2f763f13, sha256 07337d6d96d97abf2305e3b954ca3ba0827c976f12d61f0ae35536425779f049)
BibTeX
@misc{dc18fc2f763f13,
title = {Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells — Europe PMC PMID:41221272},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41221272},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_18fc2f763f13; sha256 07337d6d96d97abf2305e3b954ca3ba0827c976f12d61f0ae35536425779f049},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41221272. Agents can read the archived copy with the MCP tool read_document.